Prosecution Insights
Last updated: November 04, 2026
Application No. 18/888,230

METHODS FOR REDUCING THE SYMPTOMS OF NEURODEGENERATIVE DISEASE IN A HUMAN

Non-Final OA §102§112
Filed
Sep 18, 2024
Examiner
FERGUSON, JALISA HOLMES
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Changaris David G
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
24 granted / 39 resolved
+1.5% vs TC avg
Strong +41% interview lift
Without
With
+40.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
32 currently pending
Career history
72
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
16.8%
-23.2% vs TC avg
§102
21.2%
-18.8% vs TC avg
§112
39.1%
-0.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 39 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-20 are pending. Claims 1-20 are rejected. Claim Objections Claims 3 and 14 are objected to because of the following informalities: Claim 3 is objected to for being written in improper Markush format. The last line of the claim should state “potassium, and rubidium or combinations thereof.” Claim 14 is objected to for being written in improper Markush format. The last line of the claim should state “and rubidium or combinations thereof.” Appropriate correction is required. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 1-20 are rejected under 35 U.S.C. 112(b) being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. The term “substantially pure cis-9, trans-11 conjugated linoleic acid” in claims 1, 2, 7, 8 and 11 is a relative term which renders the claim indefinite. The term “substantially” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Paragraph [0042] on page 14 describes an example purity of the cis-9, trans-11 conjugated linoleic acid at greater than 90%, but a single example does not adequately define the term. Therefore the metes and bounds of the claim are undefined. Dependent claims 3-6 are rejected as indefinite for the same reason since they do not correct the indefiniteness issue of their parent claims. The term “about” in claims 1, 5-7, 9 and 16-19 is a relative term which renders the claim indefinite. The term “about” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. Neither the range of the molar ratio of cations to linoleic acid is sufficiently defined nor is the temperature at which the saponification reaction should took place. Therefore the metes and bounds of the claim are undefined. Dependent claims 2-4, 8, 10-15 and 20 are rejected as indefinite for the same reason since they do not correct the indefiniteness issue of their parent claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 2023/0130195 A1, which was published April 27, 2023. US ‘195 teaches a method of making an isomerized or conjugated linoleic acid cation salt in a solution or salve. See for instance claims 12-18. Example 10 in paragraphs [0071]-[0076] on pages 6 and 7 teaches instant claims 1, 9-11 and 13 since the reference discloses a method of manufacturing CLA (conjugated linoleic acid) cis-9, trans-11 octadecadienoic acid by mixing 2.5 kg water, 3 kg potassium hydroxide and 7 kg safflower oil, then heating the mixture in a microwave, then dissolving the mixture in water. Since potassium hydroxide is used in the saponification, thereby providing potassium cations, instant claims 3-4 and 14-15 are anticipated. Since the amount of potassium hydroxide relative to safflower oil is 3 kg to 7 kg, instant claims 5-6 and 16-17 are anticipated. The prior art method also teaches instant claims 2 and 12 wherein the volume of conjugated linoleic acid is at least 5 times the volume of the saponified safflower oil since the reference teaches >90% pure cis-9, trans-11 octadecadienoic acid after microwaving. See paragraph [0076] on page 7. The prior art method also discloses Example 11, see paragraph [0077], which teaches the aqueous solution of potassium safflowerate was solubilized in purified water at a concentration of 16% by weight. Further, paragraph [0082] on the same page discloses “The solution may have a concentration of the conjugated diene between 0.1 millimolar and 500 millimolar. The solution may have a concentration of the conjugated diene between 0.2 millimolar and 60 millimolar” Thus instant claims 7 and 18-19 are anticipated. The prior art method also discloses Example 12, see paragraph [0078], which teaches the addition of 10% squalane with mechanical high shearing. Thus, instant claims 8 and 20 are anticipated. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jalisa H. Ferguson whose telephone number is (703)756-1489. The examiner can normally be reached Monday - Friday 9:00am - 5:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L. Clark can be reached on (571) 272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.H.F./Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Sep 18, 2024
Application Filed
Sep 09, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758641
BRM Targeting Compounds And Associated Methods Of Use
3y 0m to grant Granted Oct 13, 2026
Patent 12753187
AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
3y 3m to grant Granted Oct 06, 2026
Patent 12709602
INTERMEDIATES FOR MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES
3y 5m to grant Granted Aug 18, 2026
Patent 12637415
LYOPHILIZED COMPOSITION COMPRISING (S)-ISOPROPYL 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE FOR INTRAVENOUS ADMINISTRATION AND THE USE THEREOF
4y 1m to grant Granted May 26, 2026
Patent 12599674
CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODS
9m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+40.8%)
3y 3m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 39 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month